drugset / Trial / NCT01456364

Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing

NCT01456364

Phase 4 Unknown 70 enrolled German Heart Center Munich
RandomizedParallel-groupOpen-labelTreatment

Summary

Clopidogrel low response is associated with a significantly higher risk for ischemic complications after percutaneous coronary intervention. Ticagrelor and prasugrel are more potent platelet inhibitory drugs and both have been shown to significantly reduce ischemic events as compared to clopidogrel. No direct comparison between ticagrelor and prasugrel in terms of their antiplatelet efficacy exists. The aim of this study is to assess the antiplatelet treatment efficacy of ticagrelor versus prasugrel over time in confirmed clopidogrel low responders undergoing percutaneous coronary intervention.

Timeline

Start
2011-09
Primary completion
2014-04
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prasugrel Small molecule 5 mg
Comparator Prasugrel Small molecule 10 mg
Comparator Ticagrelor Small molecule 90 mg